The development of novel agents for treating chronic lymphocytic leukemia (CLL) has transformed the field in recent years. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden, William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, speaks about the most promising novel agents on the scene. He includes: PI3K inhibitors; checkpoint inhibitors and their use for combatting Richters transformation; reversible BTK inhibitors; and cellular strategies like CAR T-cells. He also discusses an upcoming clinical trial, which will combine checkpoint inhibitors, CTLA-4 antibodies, and PD-1 antibodies for CLL therapy.
Novel agents in CLL: the current landscape
